Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3864728 | 0.93 | MAPT (0.57) | MAPTRXFP1KMT2AALDH1A1KDM4E | |
| SCHEMBL3867012 | 0.93 | MAPT (0.57) | MAPTRXFP1KMT2AALDH1A1KDM4E | |
| SCHEMBL3865043 | 0.93 | MAPT (0.57) | MAPTRXFP1KMT2AALDH1A1KDM4E | |
| SCHEMBL3863034 | 0.92 | MAPT (0.56) | MAPTRXFP1KMT2AALDH1A1KDM4E | |
| SCHEMBL18328447 | 0.92 | MAPT (0.56) | MAPTRXFP1KMT2AALDH1A1KDM4E | |
| SCHEMBL3864736 | 0.92 | MAPT (0.56) | MAPTRXFP1KMT2AALDH1A1KDM4E | |
| SCHEMBL3862354 | 0.91 | MAPT (0.62) | MAPTRXFP1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3867110 | 0.91 | MAPT (0.55) | MAPTRXFP1KMT2AALDH1A1KDM4E | |
| SCHEMBL3863835 | 0.90 | MAPT (0.61) | MAPTRXFP1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3863032 | 0.88 | MAPT (0.57) | MAPTRXFP1KMT2ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601856-B2 | Benzofurans as potassium ion channel modulators | WYETH (US) | 2009-10-13 | — | — | US | claimed |
| US-20080027049-A1 | Such as 2,2-Dimethyl-N-(6,7,8,9-tetrahydro-dibenzofuran-2-yl)-propionamide | WYETH (US) | 2008-01-31 | — | — | US | claimed |
| US-9751851-B2 | Molecules and compositions that inhibit gram negative bacteria and their uses | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-05 | — | — | US | disclosed |
| US-7601856-B2 | Benzofurans as potassium ion channel modulators | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601856-B2 | Benzofurans as potassium ion channel modulators | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601856-B2 | Benzofurans as potassium ion channel modulators | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080027049-A1 | Such as 2,2-Dimethyl-N-(6,7,8,9-tetrahydro-dibenzofuran-2-yl)-propionamide | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027049-A1 | Such as 2,2-Dimethyl-N-(6,7,8,9-tetrahydro-dibenzofuran-2-yl)-propionamide | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027049-A1 | Such as 2,2-Dimethyl-N-(6,7,8,9-tetrahydro-dibenzofuran-2-yl)-propionamide | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027049-A1 | Such as 2,2-Dimethyl-N-(6,7,8,9-tetrahydro-dibenzofuran-2-yl)-propionamide | KCNJ2, KCNJ5, KCNA5 | MAPT 2740/4885RXFP1 2737/4885KMT2A 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.